$200K — $250K *
Alnylam is the world’s leading RNA interference (RNAi) company.
Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality by harnessing the power of RNAi for human health as an innovative new class of medicines. We are a growing biopharmaceutical company with two approved medicines and a robust pipeline of investigational medicines focused in four strategic therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases, including several in late-stage development.
Headquartered in Cambridge, Mass., Alnylam employs over 1,400 people in 19 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe’s Top Places to Work six years in a row (2015-2020), a Great Place to Work in the U.K. and Switzerland in 2020 and Science Magazine’s #1 Top Employer in 2019 and 2020. Please visit
Partner with Global Medical Affairs team to develop new capabilities in support of externally oriented real-world clinical needs of patients, healthcare professionals, and other decision makers across internal scientific and commercial partners. They will work with the Medical Affairs Leadership Team (MALT) in the development of a forward-looking strategies that support product lifecycles and the advancement of patient care. They will work with the (MALT) to interpret and contextualize emerging data, real-world evidence and value-based strategies.
Biotechnology, or equivalent
development, and system implementations for Medical Affairs and within the pharma industry
Valid through: 1/28/2021